Manufacturers: Johnson & Johnson
JNJ-79635322 (ramantamig) is a first-in-class trispecific T-cell-engaging antibody developed by Johnson & Johnson that simultaneously binds CD3ε on T cells and the BCMA and GPRC5D antigens on myeloma cells. It is in clinical development (Phase 1, NCT05652335 and NCT06768489) for relapsed/refractory multiple myeloma, and is regarded as being in late-stage development.
JNJ-79635322 (ramantamig) is a first-in-class trispecific T-cell-engaging antibody developed by Johnson & Johnson that simultaneously binds CD3ε on T cells and the BCMA and GPRC5D antigens on myeloma cells. It is in clinical development (Phase 1, NCT05652335 and NCT06768489) for relapsed/refractory multiple myeloma, and is regarded as being in late-stage development.
T-cell-engaging trispecific antibody (TsAb) that binds the CD3ε subunit of the T-cell receptor complex on T cells together with the tumor antigens BCMA and GPRC5D on myeloma cells, redirecting T cells to induce T-cell-mediated cytotoxicity.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
